$TOVX
Theriva Biologics, Inc. Stock $tovx

$tovx Overview Financials Valuation SEC Filings Company Website

2015 Q4 Form 10-K Financial Statement

#000114420416087267 Filed on March 10, 2016

Income Statement

Concept	2015 Q4	2014 Q4	2014 Q3
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.540M	$1.860M	$1.220M
YoY Change	36.56%	19.23%	-35.45%
% of Gross Profit
Research & Development	$8.860M	$5.240M	$3.693M
YoY Change	69.08%	93.36%	150.37%
% of Gross Profit
Depreciation & Amortization	$30.00K	$10.00K	$0.00
YoY Change	200.0%	0.0%	-100.0%
% of Gross Profit
Operating Expenses	$11.39M	$7.100M	$4.911M
YoY Change	60.42%	66.28%	45.94%
Operating Profit			-$4.911M
YoY Change			45.94%
Interest Expense	$0.00	$0.00	$0.00
YoY Change			-100.0%
% of Operating Profit
Other Income/Expense, Net	$100.0K	$620.0K	$1.000K
YoY Change	-83.87%	1140.0%	-133.33%
Pretax Income	-$11.39M	-$7.101M	-$4.911M
YoY Change	60.44%	66.18%	45.94%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$11.30M	-$6.480M	-$4.910M
YoY Change	74.32%	53.37%	45.78%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.12		-$0.08
Diluted Earnings Per Share	-$0.12	-$3.115M	-$0.08
COMMON SHARES
Basic Shares Outstanding	90.81M shares	72.51M shares	58.45M shares
Diluted Shares Outstanding	90.81M shares		58.45M shares

Balance Sheet

Concept	2015 Q4	2014 Q4	2014 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$20.82M	$17.53M	$3.290M
YoY Change	18.77%	19.82%	-36.12%
Cash & Equivalents	$20.82M	$17.53M	$3.286M
Short-Term Investments
Other Short-Term Assets	$0.00	$1.548M	$1.382M
YoY Change	-100.0%	-2.7%	-16.09%
Inventory
Prepaid Expenses	$208.0K	$253.0K	$193.0K
Receivables
Other Receivables
Total Short-Term Assets	$30.34M	$19.07M	$4.668M
YoY Change	59.06%	17.62%	-31.27%
LONG-TERM ASSETS
Property, Plant & Equipment	$494.0K	$65.00K	$67.00K
YoY Change	660.0%	75.68%	-57.32%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$10.00K	$10.00K	$10.00K
YoY Change	0.0%
Total Long-Term Assets	$513.0K	$71.00K	$73.00K
YoY Change	622.54%	73.17%	-54.66%
TOTAL ASSETS
Total Short-Term Assets	$30.34M	$19.07M	$4.668M
Total Long-Term Assets	$513.0K	$71.00K	$73.00K
Total Assets	$30.85M	$19.14M	$4.741M
YoY Change	61.15%	17.76%	-31.81%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.410M	$996.0K	$873.0K
YoY Change	342.77%	601.41%	49.49%
Accrued Expenses	$297.0K	$1.298M	$111.0K
YoY Change	-77.12%	47.17%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$15.58M	$9.588M	$984.0K
YoY Change	62.44%	833.59%	69.66%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$270.0K
YoY Change
Total Long-Term Liabilities	$270.0K	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$15.58M	$9.588M	$984.0K
Total Long-Term Liabilities	$270.0K	$0.00	$0.00
Total Liabilities	$15.84M	$9.588M	$984.0K
YoY Change	65.23%	833.59%	68.49%
SHAREHOLDERS EQUITY
Retained Earnings		-$101.0M	-$94.56M
YoY Change		24.35%	22.75%
Common Stock		$110.6M	$98.32M
YoY Change		14.62%	17.88%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$16.05M	$9.556M	$3.757M
YoY Change
Total Liabilities & Shareholders Equity	$30.85M	$19.14M	$4.741M
YoY Change	61.15%	17.76%	-31.81%

Cashflow Statement

Concept	2015 Q4	2014 Q4	2014 Q3
OPERATING ACTIVITIES
Net Income	-$11.30M	-$6.480M	-$4.910M
YoY Change	74.32%	53.37%	45.78%
Depreciation, Depletion And Amortization	$30.00K	$10.00K	$0.00
YoY Change	200.0%	0.0%	-100.0%
Cash From Operating Activities	-$10.97M	-$4.780M	-$4.530M
YoY Change	129.5%	77.04%	163.37%
INVESTING ACTIVITIES
Capital Expenditures	-$40.00K	-$10.00K	-$20.00K
YoY Change	300.0%	0.0%	0.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$40.00K	-$10.00K	-$20.00K
YoY Change	300.0%	0.0%	0.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	20.00K	19.03M	0.000
YoY Change	-99.89%	55.98%
NET CHANGE
Cash From Operating Activities	-10.97M	-4.780M	-4.530M
Cash From Investing Activities	-40.00K	-10.00K	-20.00K
Cash From Financing Activities	20.00K	19.03M	0.000
Net Change In Cash	-10.99M	14.24M	-4.550M
YoY Change	-177.18%	50.05%	161.49%
FREE CASH FLOW
Cash From Operating Activities	-$10.97M	-$4.780M	-$4.530M
Capital Expenditures	-$40.00K	-$10.00K	-$20.00K
Free Cash Flow	-$10.93M	-$4.770M	-$4.510M
YoY Change	129.14%	77.32%	165.29%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2015	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	501000	USD
CY2014	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-48000	USD
CY2013	us-gaap	Operating Income Loss OperatingIncomeLoss	-12339000	USD
CY2013	us-gaap	Investment Income Interest InvestmentIncomeInterest	33000	USD
CY2013	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-1000	USD
CY2013	us-gaap	Net Income Loss NetIncomeLoss	-12317000	USD
CY2015	us-gaap	Operating Income Loss OperatingIncomeLoss	-40980000	USD
CY2015	us-gaap	Share Based Compensation ShareBasedCompensation	3198000	USD
CY2014	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	20000	USD
CY2015	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	72000	USD
CY2015	syn	Increase Decrease In Deposits And Other Assets IncreaseDecreaseInDepositsAndOtherAssets	8000	USD
CY2015	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3417000	USD
CY2015	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1001000	USD
CY2014	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16079000	USD
CY2015	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-38890000	USD
CY2014	us-gaap	Share Based Compensation ShareBasedCompensation	2459000	USD
CY2015	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8074000	USD
CY2015	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	32906000	USD
CY2014	syn	Increase Decrease In Deposits And Other Assets IncreaseDecreaseInDepositsAndOtherAssets	2000	USD
CY2015	us-gaap	Operating Expenses OperatingExpenses	40980000	USD
CY2014	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	854000	USD
CY2015	us-gaap	Investment Income Interest InvestmentIncomeInterest	6000	USD
CY2015	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3805000	USD
CY2015	us-gaap	Profit Loss ProfitLoss	-44785000	USD
CY2015	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-1048000	USD
CY2015	us-gaap	Net Income Loss NetIncomeLoss	-43737000	USD
CY2015	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	3811000	USD
CY2013	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6507000	USD
CY2013	us-gaap	Operating Expenses OperatingExpenses	12339000	USD
CY2014	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-43000	USD
CY2015	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	7971000	USD
CY2014	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	48000	USD
CY2015	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-501000	USD
CY2014	syn	Proceeds From Issuance Of Common Stock For Stock Option And Warrants Exercises ProceedsFromIssuanceOfCommonStockForStockOptionAndWarrantsExercises	4000	USD
CY2015	syn	Proceeds From Issuance Of Common Stock For Stock Option And Warrants Exercises ProceedsFromIssuanceOfCommonStockForStockOptionAndWarrantsExercises	41000	USD
CY2014	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	19027000	USD
CY2015	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	42684000	USD
CY2014	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	2900000	USD
CY2015	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	3293000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14625000	USD
CY2014	us-gaap	Interest Paid InterestPaid	0	USD
CY2015	us-gaap	Interest Paid InterestPaid	0	USD
CY2014	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2015	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2014	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	535000	USD
CY2015	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-261000	USD
CY2015	syn	Stock Issued For Milestone Payments StockIssuedForMilestonePayments	-1350000	USD
CY2014	syn	Stock Issued For Milestone Payments StockIssuedForMilestonePayments	0	USD
CY2014	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	416000	USD
CY2015	syn	Issue Of Stock For Exclusive Channel Collaboration Agreement IssueOfStockForExclusiveChannelCollaborationAgreement	-3000000	USD
CY2015	syn	Direct Offering Cost DirectOfferingCost	3357000	USD
CY2014	syn	Direct Offering Cost DirectOfferingCost	1645000	USD
CY2015	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	46000000	USD
CY2014	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	20668000	USD
CY2015	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	288000	USD
CY2014	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	0	USD
CY2013	us-gaap	Share Based Compensation ShareBasedCompensation	1669000	USD
CY2013	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	43000	USD
CY2013	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-855000	USD
CY2013	syn	Increase Decrease In Deposits And Other Assets IncreaseDecreaseInDepositsAndOtherAssets	-33000	USD
CY2013	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-253000	USD
CY2013	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7719000	USD
CY2013	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	36000	USD
CY2013	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-36000	USD
CY2013	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	12426000	USD
CY2013	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	4671000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9954000	USD
CY2013	us-gaap	Interest Paid InterestPaid	0	USD
CY2013	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2013	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2013	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	0	USD
CY2013	syn	Stock Issued For Milestone Payments StockIssuedForMilestonePayments	0	USD
CY2013	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	885000	USD
CY2013	syn	Direct Offering Cost DirectOfferingCost	1031000	USD
CY2013	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	13224000	USD
CY2013	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	0	USD
CY2015Q4	syn	Prepaid Expenses Research And Development PrepaidExpensesResearchAndDevelopment	643000	USD
CY2014Q4	syn	Prepaid Expenses Research And Development PrepaidExpensesResearchAndDevelopment	1067000	USD
CY2015Q4	us-gaap	Prepaid Insurance PrepaidInsurance	339000	USD
CY2014Q4	us-gaap	Prepaid Insurance PrepaidInsurance	228000	USD
CY2015Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	208000	USD
CY2014Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	253000	USD
CY2015Q4	us-gaap	Other Assets Current OtherAssetsCurrent	9519000	USD
CY2014Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1548000	USD
CY2015Q4	syn	Prepaid Clinical Research Organizations PrepaidClinicalResearchOrganizations	8329000	USD
CY2014Q4	syn	Prepaid Clinical Research Organizations PrepaidClinicalResearchOrganizations	0	USD
CY2015Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	105000	USD
CY2014Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	39000	USD
CY2015Q4	syn	Accrued Manufacturing Costs AccruedManufacturingCosts	0	USD
CY2014Q4	syn	Accrued Manufacturing Costs AccruedManufacturingCosts	247000	USD
CY2015	dei	Entity Registrant Name EntityRegistrantName	Synthetic Biologics, Inc.
CY2015	dei	Entity Central Index Key EntityCentralIndexKey	0000894158
CY2015	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2015	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2015	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2015	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2015	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2015Q2	dei	Entity Public Float EntityPublicFloat	173500000	USD
CY2015	dei	Trading Symbol TradingSymbol	SYN
CY2016Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	90826752	shares
CY2015Q4	syn	Accrued Vendor Payments AccruedVendorPayments	133000	USD
CY2014Q4	syn	Accrued Vendor Payments AccruedVendorPayments	176000	USD
CY2015Q4	syn	Accrued Milestone Payable AccruedMilestonePayable	0	USD
CY2014Q4	syn	Accrued Milestone Payable AccruedMilestonePayable	350000	USD
CY2015Q4	syn	Accrued Clinical Consulting Services AccruedClinicalConsultingServices	164000	USD
CY2014Q4	syn	Accrued Clinical Consulting Services AccruedClinicalConsultingServices	525000	USD
CY2015Q4	us-gaap	Equity Method Investment Ownership Percentage EquityMethodInvestmentOwnershipPercentage	0.885	pure
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	0	shares
CY2015	syn	Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod	2446	shares
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	63449	shares
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0
CY2015	syn	Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue	1.6
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	1.79
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	7974794	shares
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	7908899	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	1.8
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	1.79
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	7029808	shares
CY2014	syn	Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod	232619	shares
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	454896	shares
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.75
CY2014	syn	Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue	1.47
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	1.88
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	1.99
CY2015	dei	Document Type DocumentType	10-K
CY2015	dei	Amendment Flag AmendmentFlag	false
CY2015	dei	Document Period End Date DocumentPeriodEndDate	2015-12-31
CY2015	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
CY2015	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2015Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2015Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	90908234	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	90826752	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	72594626	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	72513144	shares
CY2015	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	80705692	shares
CY2014	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	61945356	shares
CY2013	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	45667813	shares
CY2014	syn	Issue Of Stock For Exclusive Channel Collaboration Agreement IssueOfStockForExclusiveChannelCollaborationAgreement	0	USD
CY2013	syn	Issue Of Stock For Exclusive Channel Collaboration Agreement IssueOfStockForExclusiveChannelCollaborationAgreement	0	USD
CY2015	syn	Stock Issued For License Agreement StockIssuedForLicenseAgreement	0	USD
CY2014	syn	Stock Issued For License Agreement StockIssuedForLicenseAgreement	0	USD
CY2013	syn	Stock Issued For License Agreement StockIssuedForLicenseAgreement	-425000	USD
CY2015	syn	Provision For Uncollectible Note And Interest Receivables ProvisionForUncollectibleNoteAndInterestReceivables	0	USD
CY2014	syn	Provision For Uncollectible Note And Interest Receivables ProvisionForUncollectibleNoteAndInterestReceivables	0	USD
CY2013	syn	Provision For Uncollectible Note And Interest Receivables ProvisionForUncollectibleNoteAndInterestReceivables	763000	USD
CY2015	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	0	USD
CY2014	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	0	USD
CY2013	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-58000	USD
CY2015	syn	Equipment Impairment Loss EquipmentImpairmentLoss	0	USD
CY2014	syn	Equipment Impairment Loss EquipmentImpairmentLoss	0	USD
CY2013	syn	Equipment Impairment Loss EquipmentImpairmentLoss	121000	USD
CY2015	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	0	USD
CY2014	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	0	USD
CY2013	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	1000	USD
CY2012Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	13028000	USD
CY2013Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	15230000	USD
CY2013	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1669000	USD
CY2014	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	2459000	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	3198000	USD
CY2013	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	12193000	USD
CY2014	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	11647000	USD
CY2015	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	42643000	USD
CY2013	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	232000	USD
CY2014	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	4000	USD
CY2015	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	41000	USD
CY2013	syn	Stock Issued During Period Value License Agreement StockIssuedDuringPeriodValueLicenseAgreement	425000	USD
CY2013	syn	Stock Issued Of During Period Value New Issues StockIssuedOfDuringPeriodValueNewIssues	1000	USD
CY2014	syn	Issuance Value Of Common Stock Upon Exercise Of Warrants IssuanceValueOfCommonStockUponExerciseOfWarrants	0	USD
CY2015	syn	Issuance Value Of Common Stock Upon Exercise Of Warrants IssuanceValueOfCommonStockUponExerciseOfWarrants	0	USD
CY2015	syn	Stock Issued During Period Value For Exclusive Channel Collaboration Agreement StockIssuedDuringPeriodValueForExclusiveChannelCollaborationAgreement	3000000	USD
CY2015	syn	Stock Issued During Period Valuemilestone Payment StockIssuedDuringPeriodValuemilestonePayment	1350000	USD
CY2015Q4	us-gaap	Minority Interest Ownership Percentage By Parent MinorityInterestOwnershipPercentageByParent	0.115	pure
CY2015	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2014	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2013	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	121000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	599000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	104000	USD
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2013	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	1031000	USD
CY2014	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	1645000	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	3357000	USD
CY2015Q1	us-gaap	Net Income Loss NetIncomeLoss	-12359000	USD
CY2015Q2	us-gaap	Net Income Loss NetIncomeLoss	-13623000	USD
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	-7507000	USD
CY2015Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-8207000	USD
CY2015Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-9730000	USD
CY2015Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-11650000	USD
CY2015Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-11393000	USD
CY2015	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 0pt; MARGIN: 0pt; PADDING-LEFT: 4px; PADDING-RIGHT: 0pt; FONT: 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 3pt" align="justify"></div> <h3 style="TEXT-ALIGN: justify; PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 0pt; MARGIN: 0pt; PADDING-LEFT: 4px; PADDING-RIGHT: 0pt; FONT: bold italic 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 5pt"> Use of Estimates</h3> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 0pt; MARGIN: 0pt; PADDING-LEFT: 4px; PADDING-RIGHT: 0pt; FONT: 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 3pt" align="justify">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Such estimates and assumptions impact, among others, the following: the estimated useful lives for property and equipment, fair value of warrants and stock options granted for services or compensation, respectively, estimates of the probability and potential magnitude of contingent liabilities, and the valuation allowance for deferred tax assets due to continuing and expected future operating losses. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 0pt; MARGIN: 0pt; PADDING-LEFT: 4px; PADDING-RIGHT: 0pt; FONT: 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 3pt" align="justify">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the consolidated financial statements, which management considered in formulating its estimate could change in the near term due to one or more future confirming events. Accordingly, actual results could differ from those estimates.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2015Q4	us-gaap	Net Income Loss NetIncomeLoss	-11296000	USD
CY2015Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.17
CY2015Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.19
CY2015Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.08
CY2015Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.12
CY2015Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.17
CY2015Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.19
CY2015Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.12
CY2015Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.12
CY2015Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	72673959	shares
CY2015Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	72736829	shares
CY2015Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	85974751	shares
CY2015Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	90810629	shares
CY2015Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	72673959	shares
CY2015Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	72736829	shares
CY2015Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	87585103	shares
CY2015Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	90810629	shares
CY2014Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3839000	USD
CY2014Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4651000	USD
CY2014Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4911000	USD
CY2014Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-7101000	USD
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	0	shares
CY2014Q1	us-gaap	Net Income Loss NetIncomeLoss	-3838000	USD
CY2014Q2	us-gaap	Net Income Loss NetIncomeLoss	-4556000	USD
CY2014Q3	us-gaap	Net Income Loss NetIncomeLoss	-4910000	USD
CY2014Q4	us-gaap	Net Income Loss NetIncomeLoss	-6480000	USD
CY2014Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.07
CY2014Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.08
CY2014Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.08
CY2014Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.10
CY2014Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	58324260	shares
CY2014Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	58543528	shares
CY2014Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	58543528	shares
CY2014Q4	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	65483336	shares
CY2014Q4	syn	Deferred Tax Assets Stocks Issued For Services DeferredTaxAssetsStocksIssuedForServices	585000	USD
CY2014Q4	syn	Deferred Tax Assets Stock Issued For Acquisition Of Program DeferredTaxAssetsStockIssuedForAcquisitionOfProgram	949000	USD
CY2014Q4	syn	Deferred Tax Assets Stock Issued Forlicense Agreement DeferredTaxAssetsStockIssuedForlicenseAgreement	2507000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	24657000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	28698000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	28698000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2014Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2015	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34	pure
CY2015	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0396	pure
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.3796	pure
CY2014	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34	pure
CY2014	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0396	pure
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.3796	pure
CY2013	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34	pure
CY2013	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0396	pure
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.3796	pure
CY2015	syn	Operating Loss Carryforwards Expire Date OperatingLossCarryforwardsExpireDate	2035
CY2014	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	4000	USD
CY2013	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	231000	USD
CY2015	us-gaap	Proceeds From Repurchase Of Equity ProceedsFromRepurchaseOfEquity	3000000	USD
CY2015Q4	syn	Exchange Percentage Of Unregistered Common Stock ExchangePercentageOfUnregisteredCommonStock	0.5	pure
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	1632501	shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	1632501	shares
CY2013	syn	Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod	0	shares
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	0	shares
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	1.99
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0
CY2013	syn	Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue	0
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	0
CY2015	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	424000	USD
CY2014	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	293000	USD
CY2013	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	1000000	USD
CY2015	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	108000	USD
CY2014	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	77000	USD
CY2013	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	68000	USD
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	148000	USD
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	152000	USD
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	157000	USD
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	162000	USD
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	767000	USD
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	148000	USD
CY2013Q4	syn	Warrant Liabilities WarrantLiabilities	0	USD
CY2014	syn	Issuance Of Warrants IssuanceOfWarrants	7376000	USD
CY2015Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	8300000	USD
CY2015	us-gaap	Employee Service Share Based Compensation Cash Received From Exercise Of Stock Options EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions	41000	USD
CY2014	us-gaap	Employee Service Share Based Compensation Cash Received From Exercise Of Stock Options EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions	4000	USD
CY2013	us-gaap	Employee Service Share Based Compensation Cash Received From Exercise Of Stock Options EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions	232000	USD
CY2015Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	311834	shares
CY2015Q4	us-gaap	Prepaid Expense Current And Noncurrent PrepaidExpenseCurrentAndNoncurrent	8300000	USD
CY2014Q4	us-gaap	Prepaid Expense Current And Noncurrent PrepaidExpenseCurrentAndNoncurrent	0	USD
CY2015Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	99400000	USD
CY2015	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-14870000	USD
CY2014	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-6727000	USD
CY2015	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	-1732000	USD
CY2014	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	-783000	USD
CY2014	us-gaap	Tax Adjustments Settlements And Unusual Provisions TaxAdjustmentsSettlementsAndUnusualProvisions	-687000	USD
CY2015	us-gaap	Income Tax Reconciliation Nondeductible Expense Meals And Entertainment IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment	8000	USD
CY2014	us-gaap	Income Tax Reconciliation Nondeductible Expense Meals And Entertainment IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment	13000	USD
CY2015	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	877000	USD
CY2014	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	789000	USD
CY2015	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	1447000	USD
CY2014	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-235000	USD
CY2015	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	14071000	USD
CY2014	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	7630000	USD
CY2015	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2014	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2015	us-gaap	Tax Adjustments Settlements And Unusual Provisions TaxAdjustmentsSettlementsAndUnusualProvisions	199000	USD
CY2015Q4	syn	Deferred Tax Assets Stocks Issued For Services DeferredTaxAssetsStocksIssuedForServices	922000	USD
CY2015Q4	syn	Deferred Tax Assets Stock Issued For Acquisition Of Program DeferredTaxAssetsStockIssuedForAcquisitionOfProgram	1787000	USD
CY2015Q4	syn	Deferred Tax Assets Stock Issued Forlicense Agreement DeferredTaxAssetsStockIssuedForlicenseAgreement	2308000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	37852000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	42974000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	42974000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	105000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	0	USD
CY2015Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	2200000	USD
CY2014Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	525000	USD
CY2015	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.54
CY2014	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.32
CY2013	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.27

Files In Submission

Name	View Source	Status
0001144204-16-087267-index-headers.html	Edgar Link	pending
0001144204-16-087267-index.html	Edgar Link	pending
0001144204-16-087267.txt	Edgar Link	pending
0001144204-16-087267-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
line.gif	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
spacer.gif	Edgar Link	pending
syn-20151231.xml	Edgar Link	completed
syn-20151231.xsd	Edgar Link	pending
syn-20151231_cal.xml	Edgar Link	unprocessable
syn-20151231_def.xml	Edgar Link	unprocessable
syn-20151231_lab.xml	Edgar Link	unprocessable
syn-20151231_pre.xml	Edgar Link	unprocessable
v433075_10k.htm	Edgar Link	pending
v433075_chrt-line.jpg	Edgar Link	pending
v433075_chrt-pipeline.jpg	Edgar Link	pending
v433075_exh21.htm	Edgar Link	pending
v433075_exh23x1.htm	Edgar Link	pending
v433075_exh31x1.htm	Edgar Link	pending
v433075_exh31x2.htm	Edgar Link	pending
v433075_exh32x1.htm	Edgar Link	pending
v433075_exh32x2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TOVX
Theriva Biologics, Inc. Stock $tovx

2015 Q4 Form 10-K Financial Statement

#000114420416087267 Filed on March 10, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TOVX Theriva Biologics, Inc. Stock $tovx

2015 Q4 Form 10-K Financial Statement

#000114420416087267 Filed on March 10, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TOVX
Theriva Biologics, Inc. Stock $tovx